Please assess the completion status of the following clinical trial:

Trial Title: Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological or cytological proven glioblastoma multiforme~* Recurrent or progressive disease documented by magnetic resonance imaging (MRI)~* World Health Organization (WHO) Performance status 0 - 2~* Patient may have been operated for recurrence~* For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm~* Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline MRI~Exclusion Criteria:~* Patients with histological or cytological proven glioblastoma multiforme~* Completion of radiotherapy to the brain less than 3 months prior to registration/randomization~* Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy~* Previous or current malignancy at other sites within prior 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: ACTIVE_COMPARATOR): None
- Lomustine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).